Stocktoria
EyePoint, Inc. EYPT
Nasdaq · XNAS · stock · Laboratory Analytical Instruments · website · IPO 2005-01-27
EyePoint, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -776.0% | -337.1% | -163.1% | -240.6% | -149.6% |
| Net margin | -739.4% | -302.4% | -153.8% | -247.0% | -158.1% |
| FCF margin | -775.8% | -301.1% | -3.5% | -162.2% | -136.0% |
| Return on assets | -63.7% | -31.3% | -19.9% | -56.7% | -22.2% |
| Return on equity | -75.8% | -38.9% | -26.6% | -106.1% | -31.7% |
| Debt / equity | — | — | — | 0.31× | 0.20× |
| Current ratio | 8.88 | 7.81 | 5.45 | 5.00 | 10.05 |
| Revenue growth | -27.5% | -6.0% | 11.1% | 12.1% | 7.3% |
Source: SEC EDGAR filings · CIK 0001314102 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.